The sensitivity for autoantibodies at tumor stages I and II was in the range from 3% to 13% with the exception of anti-p16 that showed a sensitivity of 33% at tumor stage I. More advanced stages (III and IV) showed higher sensitivity for all the investigated autoantibodies. Here, CDKN2A is linked to neoplasm.